RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non‐small cell lung cancer cells to anlotinib by regulating CX3CR1 ‐fractalkine expression

Adenosine deaminases acting on RNA 1 (ADAR1) has been identified to play key roles in non‐small cell lung cancer (NSCLC) progression, and can modulate the sensitivity of cancer cells to anticancer drugs. The current study aimed to investigate the effect of ADAR1 on the sensitivity of NSCLC cells to anlotinib. We established anlotinib‐resistant NSCLC (NSCLC/AR) cells, including NCI‐H1975/AR and A549/AR cells. Results showed that ADAR1 was significantly upregulated in NSCLC/AR cells. Genetic‐knockdown of ADAR1 increased the sensitivity of NSCLC/AR cells to anlotinib by inducing cell proliferation suppression, cell cycle arrest, and apoptosis. Furthermore, knockdown of ADAR1 decreased the level of C‐X3‐C motif chemokine ligand 1 (CX3CL1) in NCI‐H1975/AR and A549/AR cells after anlotinib treatment. Introduction of exogenous CX3CL1 significantly reversed the positive effect of ADAR1 deficiency on NSCLC/AR cell sensitivity, exhibited by the increase of cell viability and decrease of apoptosis. Further in‐vivo study demonstrated that knockdown of ADAR1 inhibited NCI‐H1975/AR cell tumorigenesis by reducing CX3CL1 expression. Collectively, ADAR1 deficiency increased the sensitivity of NSCLC/AR cells to anlotinib by downregulating CX3CL1, which might provide a potential strategy for NSCLC/AR therapy.